1.00 / AMA PRA Category 1 CreditTM 1.00 / CNE Contact Hours
CME/AMA credits provided by The University of Texas MD Anderson Cancer Center CNE/ANCC credits provided by AKH, Inc.
This activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and ASiM CE, LLC.
This activity is supported by educational grants from Amgen, Karyopharm Therapeutics, Sanofi Genzyme, and Takeda Oncology.
Multiple myeloma (MM) is the second most common hematological cancer and is expected to account for 12,770 deaths in 2018. It remains a largely progressive and incurable disease with frequent relapse episodes. Moreover, patients typically become refractory to both immunomodulatory drugs and proteasome inhibitors, which are the backbone of many standard treatment regimens for patients with relapsed/refractory multiple myeloma (RRMM). A number of approved and late-stage investigational agents, representing a variety of therapeutic classes, continue to demonstrate effectiveness in patients with RRMM and may address the unmet need for novel treatments among patients with highly refractory disease. This enduring panel discussion will review the efficacy and safety of emerging treatment options for patients with RRMM and discuss the clinical practice implications of these therapies in the context of currently approved therapies and treatment algorithms. This activity will also address practical strategies to individualize RRMM treatment paradigms, while considering both approved and investigational strategies, and accounting for patient-specific factors.
Hematology/oncology HCPs will be more up to date on clinical data defining the clinical utility of currently approved double and triple drug regimens for RRMM.
Hematology/oncology HCPs will be better able to access & evaluate evolving literature and clinical results regarding agents/regimens in late state development of RRMM. (Knowledge, Competence)
HCPs will be more likely to consider the most recent clinical trial data when developing & adapting treatment plans for RRMM, considering both patient- & disease specific factors. (Knowledge, Competence, Performance)
This activity is intended for hematology/oncology physicians, nurse practitioners, physicians’ assistants, and nurses, as well as other healthcare providers who are involved in the care of patients with RRMM. No prerequisites required.
Upon completion of the educational activity, participants should be able to:
REVIEW recent clinical data on the efficacy, safety, and longer-term survival data of FDA-approved agents for RRMM. (Knowledge, Competence)
EVALUATE emerging data on the efficacy, safety, and potential clinical implications on investigational targeted- and immuno-therapies for RRMM patients. (Knowledge, Competence)
INCORPORATE the most up-to-date evidence-based data into patient-specific treatment for RRMM. (Knowledge, Competence, Performance, Patient Outcomes)
Conflict Of Interest Disclosure Policy
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, made every attempt to resolve all potential conflicts of interest prior to this activity. For information on this process, please contact the CME/Conference Management at 713-792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
Disclosure Declaration It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Robert Z. Orlowski, MD, PhD (Course Director)* Professor Departments of Lymphoma/Myeloma and Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston, Texas
Dr Orlowski has disclosed the following relevant financial relationships: Advisory committee/review panel/board membership/etc - Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Sanofi-Aventis, Takeda Contracted Research - Amgen, BioTheryX, Spectrum Pharma
Donna E. Reece, MD Professor of Medicine Director Program for Multiple Myeloma and Related Diseases Princess Margaret Hospital Toronto, Ontario, Canada
Dr Reece has disclosed the following relevant financial relationships: Advisory committee/review panel/board membership/etc - Amgen, Celgene, Janssen, Karyopharm, Merck, Takeda Contracted Research - Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Otsuka, Takeda Consultant - Amgen, Celgene, Janssen Honoraria - Amgen, Celgene, Janssen
Peter M. Voorhees, MD* Director, Outreach for Hematologic Malignancies Plasma Cells Disorder Program Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute Carolinas HealthCare System Charlotte, North Carolina
Dr Voorhees has disclosed the following relevant financial relationships: Advisory committee/review panel/board membership/etc - Bristol-Myers Squibb, Celgene, Janssen, Oncopeptides, Takeda,TeneoBio Consultant - Novartis, Oncopeptides Speakers Bureau - Amgen, Janssen
PLANNING COMMITTEE Disclosures
Daniel Guinee has nothing to disclose. Jessica Marshall, PhD has nothing to disclose. Karine Cohen-Solal, PhD has nothing to disclose.
Robert Z. Orlowski, MD, PhD (Course Director)* has disclosed the following relevant financial relationships: Advisory committee/review panel/board membership/etc - Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Sanofi-Aventis, and Takeda Contracted Research - Amgen, BioTheryX, and Spectrum Pharma.
CME ACTIVITY REVIEWERS/APPROVER/STAFF DISCLOSURES
The following University of Texas MD Anderson Cancer Center, AKH Inc, and ASiM CE, LLC and AKH Inc, planners and reviewers have disclosed no financial relationships with pharmaceutical or medical product manufacturers:
The University of Texas MD Anderson Cancer Center Diane C. Bodurka, MD, BS, MPH Larry Driver, MD Petter Norman, MD
AKH, Inc Trish Brignoni, Director of Operations, AKH, Inc. Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner, AKH, Inc.
AMA PRA Category 1 Credit(s)TM
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this internet enduring material activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of
continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is awarded 1.00 Contact Hour.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 60 minutes; physicians should claim only those credits that reflect the time actually spent in the activity. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest.
The following is an interactive expert panel discussion designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the enduring expert panel, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact AKH at email@example.com.